

The 5th APEC High-Level Meeting on Health & the Economy on 30-31 August in Cebu City, Philippines.

Session 10: Providing Sustainable Access to Health Innovations through Public-Private Partnerships (10:35 – 11:15am on Monday August 31, 2015)

Prof. Chung-Liang Chien, Deputy Minister of Science and Technology, Chinese Taipei
chien@ntu.edu.tw

Dr. Nares Damrongchai, CEO, Thailand Center of Excellence for Life Sciences nares@tcels.or.th

Mr. Nicolas Chemali, Senior Director for Corporate Affairs for ASEAN, Middle East, Africa, and Turkey, Eli Lilly & Co. chemali_nicolas@lilly.com

Moderator: **Dr. Jeremy Lim**, Partner, Head of Health & Life Sciences, Asia Pacific, Oliver Wyman jeremyfylim@gmail.com

PANEL DESCRIPTION:

Providing Sustainable Access to Health Innovations through Public-Private Partnerships. How are APEC economies leveraging true partnerships in research and development; medical product regulation; and product distribution to improve access to health innovations?

SUGGESTED TOPICS:

Below are some **suggested** speaking topics for each of the speakers.

Prof. Chung-Liang Chien – the role of government in health innovation partnerships, with a focus on research, development, and commercialization.

Dr. Nares Damrongchai – the role of non-governmental organizations/academia in health innovation partnerships, with a focus on research, development, and commercialization. Present the success of the APEC Biomedical Technology Commercialization Center launched in 2014.

Mr. Nicolas Chemali – the role of industry in health innovation partnerships, with a focus on medical product regulation and product distribution.



Providing Sustainable Access to Health Innovations through Public-Private Partnerships

CHUNG-LIANG CHIEN
CHINESE TAIPEI



1


Chairman, Dr. Lim, Ladies & Gentlemen, Good Morning:

It's my honor and pleasure to share our experiences from Chinese Taipei. From the Government point of view, we should provide a pathway for public-private partnership, especially for Biotech-industry.

What we have done? We launched the Diamond Action Plan for Biotech Take Off since 2009.

GOVERNMENT POLICY AND STRATEGIES: DIAMOND ACTION PLAN FOR BIOTECH TAKEOFF (2009)

*To Develop Taiwan into A New drug and Medical Device R&D House
and An Asian R&D Partner for the Global Community*



Our goal is to develop Taiwan into a New Drug and Medical Device R&D House, as well as an Asian R&D partner for the Global Community.

We put a lot of efforts to promote the translational Research including the arrangement of National Research Program for Biopharmaceuticals to bridge upstream innovations of discovery research with downstream commercialization of biotech companies. Almost at the same time, we reorganized our departments to establish Taiwan FDA, and try to set up regulatory environment of international standards.


Besides TFDA, a non-profit organization, Center of Drug Evaluation (CDE) also setup to assist TFDA in performing the review of Medical products and related services.

More than that, we all know Biotech industry need money for the commercialization.

So we tried to establish a Biotech Venture Capital (BVC) to attract Private Funding matching with National Development Fund. We have also established the “Supra Incubation Center”, in order to make hubs through incubation of Pharmaceuticals & Medical Device startup companies.



TAIWAN BIOTECH TAKE-OFF ACTION PLAN (2013)



After 4 years, in 2013, at that year, I got a position in the government at Board of Science & Technology (BOST). I tried to help to modify the Action Plan for Biotech. We figured out that the collaboration between Ministries or Departments is very important. So we tried to link Ministry of Economic Affairs (MOEA), National Science Council (NSC, now is Ministry of Science & Technology), and DOH (Now is Ministry of Health & Welfare) to work together.

For MOEA, they helped to establish the Pharmaceuticals Pre-clinical Core, as well as the Rapid-Prototyping Center for Medical Devices. These Core facilities give big helps for our new startup companies.

For NSC, we modified the SIC to SI²C, Supra-Integration and Incubation Center, more emphasis on the function of integration.

We provide legal, IPR, technical, and operation commercialization services. We also tried to integrate the resources for factory incubations, especially in our Science Parks.

For DOH, they did good jobs on the establishment of an integrated and transparent evaluation process of Medical Products, as well as Promotion of Regional regulatory harmonization. Actually, we learned a lot from APEC meeting about this issue.

SUPRA INTEGRATION AND INCUBATION CENTER (SI2C)



Today, I would like to elaborate more about SI2C that supported by MOST.

We all know that there is a valley of Death between Research Discovery from Academia and full scale production from new company.

What we could try to help? Just make a "Bridge"!!

SI2C tried to make the connections of the value chain, including play as angel to provide the seed fund.

We also help to screen or identify the most potential projects with the assistance of some senior experts from industrial or venture capital fields.

SI2C is also fostering & securing young talents for the future biotech. For example, with the assistance from Stanford University, we created a Stanford- Taiwan Biotech (STB) Program to train our young PhDs and MDs. And encourage them to run startup companies with their own brilliant idea.

Nevertheless, the SI2C is also helping us to build-up Taiwan Biomedical Ecosystem.

Let me give you an example, the Hsinchu Biomedical Science Park.


Hsinchu Biomedical Science Park



This Park is just next to our famous Science Park with strong ICT industry. We will focus on the Medical Device with the supports of R&D teams from ICT. Not only SI2C plays an important role in this Science Park. We also invited the rapid prototyping center supported by ITRI (Industrial Technology Research Institute) as well as National Laboratory Animal Center to join in this Park, and help the potential pre-clinical tests all in one place.

Now there are more than 30 new startup companies in this Science Park and soon become a cluster for the Medical Device Industry.

**TAIWAN CLINICAL TRIAL CONSORTIUM (TCTC):
TOTAL SOLUTION AND EARLY ENGAGEMENT FOR GLOBAL MARKET**



The last I would like to introduce to you is “Taiwan Clinical Trial Consortium” (TCTC). This is supported by the National Research Program for Biopharmaceuticals from MOST.

As Minister Chiang introduced our health care system yesterday. We have more than 20 Medical Centers all over the island. With the great helps from senior professors of Medical Centers, finally, we could group them up as consortium by the Disease Patterns. Such as lung cancer consortium, if you, from the international big Pharma, would like to test your clinical trials for lung cancer, just apply one IRB and get the approval, you could have more than 10 medical centers to run your clinical trials at the same time. It’s good! Right?

So welcome to Taiwan. Welcome to Chinese Taipei.

Thank you very much for your attention. Thank you!



Speaker: Prof. Chung-Liang Chien – the role of government in health innovation partnerships, with a focus on research, development, and commercialization.



Speaker: Prof. Chung-Liang Chien – Presentation of The Action Plan for Biotech Take Off (2013).



**Asia-Pacific
Economic Cooperation**



APEC
PHILIPPINES
2 0 1 5

LSIF Executive Board

**Briefing Materials for the 5th APEC High-Level Meeting on
Health & the Economy, LSIF Executive Board Meeting, and the
LSIF Special Session**



CEBU CITY, PHILIPPINES

29-31 August 2015



Members of the APEC Life Sciences Innovation Forum Executive Board 2015.

Janette Garin (Chair, Secretary of Health, Philippines) (The first row, middle);

Ryan MacFarlane (LSIF Planning Group Chair, The first Left 1);

Fikry Issac (LSIF Executive Board Industry Co-Chair, The first Right 1);

Peter Sheehan (LSIF Executive Board Academic Co-Chair, The first Right 2);

Nares Damrongchai (LSIF Executive Board Government Co-Chair, The first Left 2);

Kate Clemans (Advisor to the LSIF Co-Chairs; The second Right 2)

Chung-Liang Chien (LSIF Research & Development Steering Committee Chair; The third Right 2)

LSIF Organizational Chart



2015 LSIF Executive Board Meeting
 Saturday, 29 August 2015
 Cebu, Philippines, Waterfront-Lalug Arctic 3
 17:00 – 19:00

DRAFT AGENDA

Time	#	Topic
17:00 – 17:05	1	Welcoming Remarks and Introductions of LSIF Executive Board Members
17:05 – 17:10	2	Overview of the LSIF and the Role of the LSIF Executive Board
17:10 – 17:35	3	Discussion on the Activities and Future Direction of the LSIF Research & Development Steering Committee (RDSC)
17:35 – 18:00	4	Discussion on the Activities and Future Direction of the LSIF Regulatory Harmonization Steering Committee (RHSC)
18:00 – 18:25	5	Discussion on the Activities and Future Direction of Health and Innovation Workstreams
18:25 – 18:35	6	Discussion on Collaboration with Other APEC Fora and International Organizations
18:35 – 18:45	7	Other Items for Discussion and Consideration
18:45 – 18:55	8	Looking Ahead to 2016
19:00	9	Adjourn